SAB Biotherapeutics presents Phase 1 data for SAB-142 in type 1 diabetes at EASD meeting

PUBT · 1d ago
SAB Biotherapeutics presents Phase 1 data for SAB-142 in type 1 diabetes at EASD meeting
  • SAB Biotherapeutics flagged fresh Phase 1 data for SAB-142 in Stage 3 type 1 diabetes, positioning it as a redosable immunotherapy.
  • Results will be presented in future sessions at the European Association for the Study of Diabetes meeting in Milan on Sep. 28–30, 2026.
  • Disclosed outcomes include early signs of preserving patients’ insulin production, supportive mechanism-of-action evidence, and a safety profile consistent with repeat dosing.
  • Additional readouts cover predictable drug behavior in the body, limited immune reaction risk, and early activity signals in patients with remaining beta-cell function.
  • The program is advancing into the registrational SAFEGUARD study, a key step toward potential approval in the company’s lead indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220830PRIMZONEFULLFEED9829300) on September 22, 2026, and is solely responsible for the information contained therein.